Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its 2020 Q1 net loss rose about 97 percent year over year, as it reached the cusp of recognizing its first ever revenues.

The liquid biopsy firm's net loss for the three months ended March 31 was $7.7 million, or $0.13 per share, compared to $3.9 million, or $.08 per share, in the same quarter last year, exceeding the consensus Wall Street estimate of a loss of $0.11 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US has sent its formal notice of withdrawal from the World Health Organization, according to the Wall Street Journal.

Science reports that a draft spending bill would increase the US National Institutes of Health budget by 13 percent.

The Harvard Crimson reports that Harvard and MIT are suing the Department of Homeland Security and ICE over the new international student visa policy.

In Nucleic Acids Research this week: algorithm to determine molecular sequence types and other microbial features, computational method to uncover R-loop structures, and more.